Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The ...
read more
Wednesday, December 19, 2012
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced that Dr. Kenneth Miller has been appointed Senior Vice President of R&D at IGI Laboratories, Inc. effective December 17, 2012.
read more
Wednesday, November 06, 2013
Jason Grenfell-Gardner, President and CEO of the Company, commented, "This submission brings our total number of abbreviated new drug applications on file with the FDA to thirteen. We believe our current pipeline of submissions pending approval by ...
read more
Thursday, September 19, 2013
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its fourth abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company's ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the ...
read more
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company’s ...
read more
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based pharmaceutical company, today announced that Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of IGI Laboratories, Inc. effective July 30, 2012.
read more
Monday, November 11, 2013
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received formal approval from the U.S. Food and Drug Administration (FDA) of its supplemental filing for the site transfer of ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has received tentative approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) ...
read more
IKA Works is now officially 3-A CIP certified for our High Shear Mixer, Multiple Stage Homogenizer and Solid-Liquid Disperser.
read more
Thursday, January 11, 2018
IKA Works is now 3-A CIP certified for the company’s High Shear Mixer, Multiple Stage Homogenizer and Solid-Liquid Disperser.
read more
Wednesday, October 14, 2020
Iksuda has executed its option to secure exclusive, worldwide rights to develop a novel class of tumor-activated prodrug payloads from the University of Goettingen.
read more
Iktos announced a collaboration agreement with Merck KGaA, Darmstadt, Germany, where Iktos generative modelling AI will be used to facilitate discovery and design of compounds for Merck KGaA.
read more